Talking about the outlook for the pharmaceutical industry in India, KRN Moorthy, Deputy Managing Director, Wanbury said that the pharmaceutical industry should do well in the coming years.
In my opinion the domestic market should grow by 15% which is significant. Exports to the developed countries might see downside in keeping with the difficult phase these countries are passing through. However this would probably be an interim phase. Part of this could be offset by the buoyancy noticed in the emerging markets, he added.
Moorthy said that it is the time to exercise corporate prudence and channelize ones efforts. Wanbury is seeing a big opportunity in the contract research and manufacturing services (CRAMS) segment.
Mumbai-based pharma firm Wanbury has set a target of Rs 10 billion revenue by 2012. The company has a strong presence in domestic branded formulations. Its major thrust area also lies in active pharmaceutical ingredient (API) and contract research and manufacturing services (CRAMS).
Speaking on the company`s expansion plans Mr. Moorthy said, “ We will do a business of Rs 10 billion by 2012.“ In terms of the Indian business, we have been ranked at 48th position by ORG-IMS, Moorthy said.
The company received the “Best Brand Launch“ by ORG-IMS for Cpink and Rabiplus brands. CPink is a hematinic, typically used for anemia, pregnancy-related anemia or any iron deficiency. Rabiplus is anti-ulcer.
Wanbury is soon launching two new divisions in domestic formulations. The company will also launch about 15 products in fiscal year 2010 in all the five divisions. It will launch 5 new products for CRAMS and 3 products for APIs for which the patent is expiring after 2014. “This will be welcome additions to our revenues, “ Moorthy said.